Chemistry:Lucid-MS
Lucid-MS, also known as Lucid-21-302, is a protein arginine deiminase 2 (PAD2) inhibitor which is under development for the treatment of multiple sclerosis.[1][2][3][4] It is taken orally.[1][4]
The drug is described as a non-immunomodulatory neuroprotective agent against demyelination and is said to be a potential first-in-class medication.[1][3][4] The pharmacokinetics of Lucid-MS have been described.[3][4]
It was originated by University Health Network and has been developed by FSD Pharma, Lucid Psycheceuticals, and Quantum Biopharma.[1][2][3] As of February 2026, Lucid-MS is in phase 1 clinical trials, with at least one phase 1 trial having been completed and published.[1][2][3][4] A phase 2 trial is being planned.[3] The chemical structure of Lucid-MS does not yet appear to have been disclosed.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Lucid MS". AdisInsight. Springer Nature Switzerland AG. 16 March 2025. https://adisinsight.springer.com/drugs/800065213.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Lucid 21 302 with Synapse". 13 December 2025. https://synapse.patsnap.com/drug/6a72dc057df84ec9b3570b874bfbc980.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 "Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers". 27 March 2026. https://www.neurologylive.com/view/myelin-protective-small-molecule-lucid-ms-promising-early-stage-data-healthy-volunteers.
- ↑ 4.0 4.1 4.2 4.3 4.4 "P131 / P131 - Results of a Phase 1 Multiple Ascending Dose Trial of Lucid-21-302 (Lucid-MS) in Healthy Volunteers: A Novel Myelin Protective Small Molecule to Prevent Disease Progression in Multiple Sclerosis.". 2026 ACTRIMS Forum. San Diego, CA.. February 2026. Abstract P131. https://www.abstractsonline.com/pp8/#!/21408/presentation/615.
External links
 |  |
